cas 114778-50-6|| where to buy (R)-O-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)hydroxylamine

Nom du produit:(R)-O-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)hydroxylamine

IUPAC Name:O-{[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}hydroxylamine

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM122019-1g	in stock	țƎȁ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Notes supplémentaires

Verification code*

refresh

: N° CAS:114778-50-6; Formule moléculaire:C6H13NO3; Point de fusion:-; Code SMILES:NOC[C@@H]1OC(C)(C)OC1; Densité:

: Numéro de catalogue:CM122019; Poids moléculaire:147.17; Point d'ébullition:; N° Mdl:MFCD09263188; Stockage:Store at 2-8°C.

: Dioxolanes; Dioxolane is a heterocyclic acetal with the formula (CH2)2O2CH2. It is related to tetrahydrofuran by exchanging an oxygen for the CH2 group. The isomer 1,2-dioxolane (in which the two oxygen centers are adjacent) is a peroxide. 1,3-Dioxolane is used as solvent and comonomer in polyacetal. The dioxolane-type and their hydrogenolysis can provide very valuable partially protected building blocks either for oligosaccharide syntheses or sugar transformations.

: Alicyclic Heterocycles; When the ends of the chains are joined together into a ring, cyclic compounds result; such substances often are referred to as carbocyclic or alicyclic compounds. Substitution of one or more of the ring carbon atoms in the molecules of a carbocyclic compound with a heteroatom gives a heterocyclic compound.

: Mirdametinib; SpringWorks Therapeutics announced that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The NDA submission includes data from the Phase 2b ReNeu trial. The primary endpoint was confirmed objective response rate (ORR). The BICR-confirmed objective response rate was 52% in pediatric patients and 41% in adult patients. Mirdametinib treatment showed deep and durable responses and demonstrated significant improvements in key secondary patient-reported outcome measures.